Recent events
Recent events tied to this brand in public sources.
Back to profile33 entries · Page 1 of 2
2022
Dr. Reddy's completes acquisition of Nimbus Health
Dr. Reddy's Laboratories completed its acquisition of Nimbus Health GmbH. Nimbus Health became a wholly owned step-down subsidiary of Dr. Reddy's with effect from 24 February 2022.
2022
Dr Reddy's launches Molflu in India
Dr Reddy's Laboratories launched molnupiravir capsules under the Molflu brand in India at Rs 35 per capsule. The company said the product was expected to become available in pharmacies from early the following week.
2021
Mintop launches minoxidil treatment for female pattern hair loss in India
Dr. Reddy's announced the launch of minoxidil products for women under the Mintop and Mintop Eva brand names following India's first approval of the treatment indication for female pattern hair loss.
2021
Novartis and Dana-Farber sue Dr. Reddy’s over generic Rydapt
Novartis Pharmaceuticals and Dana-Farber Cancer Institute filed a complaint alleging that Dr. Reddy’s Laboratories infringed Novartis’s patent for Rydapt through its proposed generic leukemia treatment. The allegations are claims in the lawsuit, not a court finding.
2021
Dr Reddy's announces commercial launch of 2-DG
Dr Reddy's Laboratories announced the commercial launch of 2-DG, a COVID-19 treatment drug, at a maximum retail price of Rs 990 per sachet. It said initial availability would be in hospitals across metros and Tier 1 cities, followed by expansion to the rest of India.
2021
Aster DM Healthcare partners with Dr Reddy's to administer Sputnik V
Aster DM Healthcare said it had partnered with Dr Reddy's Laboratories to administer Sputnik V in a limited pilot soft launch, initially in Kochi, Kerala, and Kolhapur, Maharashtra.
2021
Rockwell and Dr. Reddy’s partner on vaccine freezers
Rockwell Industries joined hands with Dr. Reddy’s Laboratories to provide WHO PQS-certified Covid-19 vaccine freezers for storage of the Sputnik V vaccine across India.
2021
First batch of 2-DG COVID-19 medicine released
The first batch of the 2-deoxy-D-glucose (2-DG) COVID-19 drug, developed by DRDO in collaboration with Dr Reddy's Laboratories, was released by India's defence minister.
2021
Dr. Reddy's Laboratories enters partnership agreement with ABCD Technologies
Dr. Reddy's Laboratories entered into a partnership agreement with ABCD Technologies LLP, which is to be renamed IndoHealth Services LLP.
2021
Dr. Reddy's recalls prescription drug blister packages
Dr. Reddy's recalled approximately 21,400 blister packages of specified prescription medications because the packaging was not child resistant and could pose a poisoning risk if young children swallowed the contents. No incidents or injuries had been reported.
2020
Dr. Reddy's agrees to acquire selected Glenmark brands
Dr. Reddy's Laboratories announced a definitive agreement to acquire selected anti-allergy brands and associated intellectual property rights from Glenmark Pharmaceuticals for specified territories, subject to precedent actions and closing activities.
2020
Dr Reddy's announces clinical-trial advisory partnership with BIRAC
Dr Reddy's Laboratories announced a partnership with BIRAC for advisory support on clinical trials of the Sputnik V COVID-19 vaccine in India. The partnership provides access to some BIRAC-funded clinical trial centres and good clinical laboratory practice labs for immunogenicity testing.
2020
Dr. Reddy’s appoints Parag Agarwal as CFO
Dr. Reddy’s Laboratories announced that Parag Agarwal would join as Chief Financial Officer (Designate) on November 2, 2020, and that the board had approved his appointment as Chief Financial Officer effective December 1, 2020.
2020
Dr. Reddy’s discloses ransomware attack
Dr. Reddy’s Laboratories said the cyber attack it had detected the previous week involved ransomware. The company said it had isolated impacted IT services and that its investigation had not determined whether any data breach involved personally identifiable information.
2020
Dr. Reddy’s and Celgene settle Revlimid patent litigation
Dr. Reddy’s announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy’s to sell volume-limited generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026.
2020
Dr. Reddy's signs Sputnik V trial and distribution deal for India
Dr. Reddy's Laboratories signed a deal with the Russian Direct Investment Fund to conduct a clinical trial and distribute the Sputnik V COVID-19 vaccine in India. The fund is to supply 100 million doses, and the trials and supply deal depend on approval from India's central drug regulator.
2020
Dr Reddy’s launches Redyx in India
Dr Reddy’s Laboratories launched Remdesivir under the Redyx brand in India. The article reports that the medicine was approved for restricted emergency use for certain hospitalised COVID-19 patients.
2020
Dr. Reddy's partners with Encube Ethicals to bring gel to market
Dr. Reddy's Laboratories partnered with Encube Ethicals to bring its Diclofenac Sodium topical gel to market.
2020
Dr. Reddy's launches Avigan in India
Dr. Reddy's announced the launch of Avigan (Favipiravir) 200 mg tablets in India. The article says the drug was approved by India's DCGI for treating patients with mild to moderate COVID-19.
2020
Fujifilm partners with Dr. Reddy’s and Global Response Aid to commercialize Avigan overseas
Fujifilm said it was partnering with Dr. Reddy’s Laboratories to sell Avigan in India and elsewhere for COVID-19 treatment. Under the agreement, Fujifilm Toyama Chemical would grant Dr. Reddy’s and Global Response Aid rights to develop, make and sell Avigan overseas in return for a lump-sum license fee and royalties on sales.